PanGen Biotech Inc. (KOSDAQ:222110)
South Korea · Delayed Price · Currency is KRW 5,030.00
-80.00 (-1.57%)
At close: Jun 5, 2026
PanGen Biotech Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 13,707 | 13,417 | 14,673 | 7,315 | 6,501 | 7,936 |
Other Revenue | -0 | -0 | -0 | -0 | - | - |
| 13,707 | 13,417 | 14,673 | 7,315 | 6,501 | 7,936 | |
Revenue Growth (YoY) | -6.37% | -8.56% | 100.58% | 12.53% | -18.08% | 28.18% |
Cost of Revenue | 9,266 | 8,919 | 9,534 | 6,343 | 5,858 | 7,420 |
Gross Profit | 4,441 | 4,498 | 5,139 | 971.8 | 642.47 | 515.69 |
Selling, General & Admin | 1,744 | 1,653 | 1,768 | 1,536 | 1,272 | 969.85 |
Research & Development | 1,447 | 1,382 | 2,012 | 3,332 | 3,850 | 2,734 |
Amortization of Goodwill & Intangibles | 125.22 | 124.89 | 124.06 | 111.88 | 46.82 | 40.05 |
Other Operating Expenses | 33.84 | 29.78 | 26.32 | 26.64 | 25.92 | 28 |
Operating Expenses | 3,153 | 2,991 | 4,118 | 5,197 | 5,233 | 3,804 |
Operating Income | 1,288 | 1,506 | 1,020 | -4,225 | -4,591 | -3,288 |
Interest Expense | -151.92 | -145.87 | -322.1 | -220.68 | -128.77 | -293.25 |
Interest & Investment Income | 425.01 | 424.43 | 184.78 | 41.75 | 246.57 | 179.7 |
Currency Exchange Gain (Loss) | 234.34 | -8.17 | 172.79 | 12.47 | 7.34 | 92.88 |
Other Non Operating Income (Expenses) | 273.06 | 273.52 | -91.83 | -64.6 | 37.97 | 59.88 |
EBT Excluding Unusual Items | 2,068 | 2,050 | 963.8 | -4,457 | -4,428 | -3,249 |
Gain (Loss) on Sale of Assets | -0.21 | 17.01 | 13.94 | 15.15 | -0.24 | -0.67 |
Other Unusual Items | - | - | 25.85 | - | -7.39 | - |
Pretax Income | 2,068 | 2,067 | 1,004 | -4,441 | -4,435 | -3,250 |
Income Tax Expense | 2.91 | 16.53 | 59.9 | 47.43 | 58.69 | 60.5 |
Net Income | 2,065 | 2,051 | 943.69 | -4,489 | -4,494 | -3,310 |
Net Income to Common | 2,065 | 2,051 | 943.69 | -4,489 | -4,494 | -3,310 |
Net Income Growth | 28.01% | 117.30% | - | - | - | - |
Shares Outstanding (Basic) | 13 | 13 | 12 | 11 | 11 | 10 |
Shares Outstanding (Diluted) | 14 | 13 | 12 | 11 | 11 | 10 |
Shares Change (YoY) | 14.18% | 17.05% | 7.68% | 0.13% | 4.47% | 6.02% |
EPS (Basic) | 153.40 | 154.43 | 82.00 | -420.00 | -421.00 | -324.00 |
EPS (Diluted) | 145.10 | 146.00 | 82.00 | -420.00 | -421.00 | -324.00 |
EPS Growth | 7.55% | 78.05% | - | - | - | - |
Free Cash Flow | -672.93 | -373 | 2,627 | -3,873 | -4,231 | -4,749 |
Free Cash Flow Per Share | -49.29 | -27.69 | 228.26 | -362.36 | -396.34 | -464.83 |
Gross Margin | 32.40% | 33.52% | 35.02% | 13.29% | 9.88% | 6.50% |
Operating Margin | 9.39% | 11.23% | 6.95% | -57.76% | -70.62% | -41.44% |
Profit Margin | 15.07% | 15.28% | 6.43% | -61.36% | -69.13% | -41.72% |
Free Cash Flow Margin | -4.91% | -2.78% | 17.90% | -52.94% | -65.08% | -59.85% |
EBITDA | 2,767 | 2,972 | 2,489 | -2,629 | -2,987 | -1,756 |
EBITDA Margin | 20.19% | 22.15% | 16.96% | -35.94% | -45.96% | -22.13% |
D&A For EBITDA | 1,480 | 1,465 | 1,468 | 1,597 | 1,603 | 1,532 |
EBIT | 1,288 | 1,506 | 1,020 | -4,225 | -4,591 | -3,288 |
EBIT Margin | 9.39% | 11.23% | 6.95% | -57.76% | -70.62% | -41.44% |
Effective Tax Rate | 0.14% | 0.80% | 5.97% | - | - | - |